On Wednesday, November 8th, the US Food and Drug Administration (FDA) announced that the weight loss average of 72 weeks exceeded 40 pounds! The price is 20% lower, and the weight loss drug that challenges Smeglutide has arrived, Eli Lilly's injection with the trade name of Zepbound (Tirzepatide) is approved for long-term weight management of adults who are obese (BMI index 30 or higher) or overweight (BMI index 27 or higher) and have at least one weight related disease (such as hypertension, type II diabetes or high cholesterol).